WORCESTER, Mass., Oct. 21, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced it has received its first purchase order for Generex Oral-lyn(TM) from Continental Pharm Laboratories, a pharmaceutical products distributor in Algeria. The order consists of 10,000 canisters of Generex Oral-lyn(TM) which will be filled by the Company's Middle Eastern branch office, Generex MENA (Middle East and Northern Africa), located in Dubai Healthcare City.

"We are pleased that the first order for Generex Oral-lyn(TM) has come so quickly on the heels of the launch in Algeria last week," said Bill Abajian, Sr. Executive Advisor, Global Business Development and Licensing for the Company. "It is a testament to the enthusiasm demonstrated by the endocrinologists to introduce Generex Oral-lyn(TM) to their patients' treatment paradigm and to the education and training strategy tailored to the region and implemented by the Generex MENA office."

Generex MENA is responsible for over 20 countries and has relationships with over 31 distributors for each of the various product lines and territories who have already begun commercializing the Company's confectionary product lines, and out of those countries, eight are actively pursuing regulatory approval for Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and have filed the Generex Oral-lyn(TM) dossier with their respective regulatory authorities.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp.